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Background: Matrix metalloproteinases (MMPs) and C-reactive protein (CRP) are involved in chronic obstructive
pulmonary disease (COPD) pathogenesis. The aim of the present work was to determine plasma concentrations of
MMPs and CRP in COPD associated to biomass combustion exposure (BE) and tobacco smoking (TS).
Methods: Pulmonary function tests, plasma levels of MMP-1, MMP-7, MMP-9, MMP-9/TIMP-1 and CRP were
measured in COPD associated to BE (n = 40) and TS (n =40) patients, and healthy non-smoking (NS) healthy women
(controls, n = 40).
Results: Plasma levels of MMP-1, MMP-7, MMP-9, and MMP-9/TIMP-1 and CRP were higher in BE and TS than in the
NS healthy women (p <0.01). An inverse correlation between MMP-1, MMP-7, MMP-9, MMP-9/TIMP-1 and CRP
plasma concentrations and FEV1 was observed.
Conclusions: Increase of MMPs and CRP plasma concentrations in BE suggests a systemic inflammatory phenomenon
similar to that observed in COPD associated to tobacco smoking, which may also play a role in COPD pathogenesis.
Keywords: Biomass combustion exposure, C-reactive protein, Chronic obstructive pulmonary disease, FEV1,
Metalloproteinases, Tobacco smokingIntroduction
Chronic obstructive pulmonary disease (COPD) is a
leading cause of mortality and morbidity worldwide [1].
Although tobacco smoking is well recognized as the
major risk factor for the disease, exposure to biomass
smoke (BE) and other fuel combustion products has also
been described as an additional risk factor [2,3]. The
association between BE, mainly wood smoke and COPD
in different populations, particularly in developing coun-
tries where wood is used as fuel for cooking and heating,
has been established [4-6]. The clinical profile of COPD
associated with BE and its prognostic factors have been
described in Mexican population [3,5]. Women are more
susceptible than men to this disease exhibiting bronchial* Correspondence: carlos.ramos26@yahoo.com.mx
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unless otherwise stated.symptoms, decreased exercise capacity, changes in
quality of life, and augmented use of healthcare services
and supplemental oxygen. Nevertheless, a lot of ques-
tions about its pathogenesis and molecular mechanisms
associated with biomass combustion exposure remain
unanswered [2,3].
Several recent reports have suggested that a persistent,
low-level, systemic inflammation plays a significant patho-
genic role in COPD. Accordingly, elevated circulating
levels of C-reactive protein (CRP) among other inflam-
matory markers [7], such as plasma and sputum matrix
metalloproteinases (MMPs) and the tissue inhibitor of
metalloproteinase-(TIMP)-1 levels have been reported,
suggesting their participation in the pathogenesis of
COPD secondary to TS [8-11].
Despite the growing evidences of BE as a risk factor for
COPD, very little information on systemic inflammational Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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so far, there are few studies describing inflammatory mole-
cules associated to changes in FEV1 in COPD due to BE.
The aim of the present study was to determine plasma
concentrations of matrix metalloproteinase-(MMP)-1,
MMP-7, MMP-9, MMP-9/TIMP-1, and CRP in COPD
associated with BE, specifically to wood smoke. A group
of non-smoking (NS) healthy women was considered as
control group and data were compared with subjects
having COPD associated to tobacco smoke (TS).
Materials and methods
Study population
Eighty women with a clinical and functional diagnosis of
COPD associated with BE or tobacco smoke were re-
cruited from the COPD Clinic from January to Decem-
ber 2013. The quantity of tobacco smoked and the
degree of exposure to BE was determined by a clinical
interview, using the Spanish version of a validated in-
strument that was modified to include additional ques-
tions directly related to fuels used for cooking and
heating [12]. The main inclusion criterion was a history
of daily wood smoke exposure for at least 200 hours/
year or a history of tobacco smoking of at least >10
pack/year. Cumulative exposure to wood smoke was
expressed as hours/year, which was calculated by multi-
plying the number of years of cooking with wood by the
average of daily hours spent cooking [5].
COPD diagnosis was confirmed by medical history
and spirometry results, which were interpreted accord-
ing to the GOLD criteria [13]. We excluded from the
study groups those subjects who had both BE and to-
bacco exposure or a history of other chronic pulmonary
conditions such as asthma, tuberculosis or bronchiec-
tasis. Patients with COPD that participated in this study
were clinically stable, with no history of exacerbations
for at least 6 weeks prior to the study. Forty healthy
non-smoking (NS) women volunteers with normal spir-
ometry values, without a history of tobacco smoking or
biomass smoke exposure, with no signs of infectious re-
spiratory disease during the past 3 weeks and no history
of asthma, allergy or other diseases were considered as
the control group.
Informed consent was obtained from each subject
and the protocol was approved by the local Ethic and
Research Committees at the Instituto Nacional de




All subjects were evaluated through spirometry both
pre- and post-bronchodilator following the procedures
recommended by the American Thoracic Society/EuropeanRespiratory Society [14]; accordingly, a dry rolling-seal
volume spirometer (Sensormedics, Yorbalinda, CA, USA)
was used, and Mexican standard reference equations were
applied [15]. These reference equations are similar to the
National Health and Nutrition Examination Survey III
values for Mexican-Americans [16].
Diagnosis of COPD was established according to the
history of tobacco smoking or wood smoke exposure
and pulmonary function tests after inhalation of 400 μg
of salbutamol [13].
Venous blood samples were collected from COPD pa-
tients and NS in 5 mL lithium heparin-coated tubes,
centrifuged and plasma protein content was measured
by the bincinchoninic acid protein assay (Pierce Chem-
ical Company, Rockford, IL, USA) [17]. Plasma samples
were stored at -70°C until analyzed.
Plasma MMPs and CRP quantification
Concentrations of plasma MMP-1, MMP-7, MMP-9,
MMP-9/TIMP-1 complex (duo set) and CRP were de-
termined by commercially available ELISA kits (R&D
Systems, Minneapolis, MN, USA), according to the
manufacturers’ instructions. The detection limits were:
0.023 ng/mL for MMP-1, 0.016 ng/mL for MMP-7,
0.36 ng/mL for MMP-9, 10.0 pg/mL for TIMP-1 and
0.02 μg/mL for C-reactive protein.
Statistical analysis
Data were expressed as mean ± SD for at least three in-
dependent experiments. One-way analysis of variance
(ANOVA) followed by Tukey’s test were used to adjust
multiple comparisons between groups. Associations be-
tween variables were performed using Pearson’s correl-
ation coefficient (r). The SPSS software for Windows
(Chicago, IL) was used for statistical analyses; p <0.05
was considered statistically significant.
Results
Patients’ clinical characteristics
General clinical characteristics of COPD patients with
BE or tobacco smoke and control subjects are shown in
Table 1. Patients with BE were significantly older, shorter
and with higher BMI than tobacco smoke subjects and
healthy control women. The mean exposure to biomass
was 230 ± 132 hours/year, whereas smokers had a mean
cumulative tobacco consumption of 50 ± 30 pack/year.
Despite women with BE showing a significantly lower
SaO2, no differences were observed in the domains of
the CRQ nor in the GOLD stages (Table 1).
Pulmonary function tests
Both FEV1 (% predicted) and FVC (% predicted) were
significantly lower in women with COPD associated to
smoking in comparison to control healthy women and
Table 1 Clinical characteristics of COPD and NS healthy women (control)
Control n = 40 BE n = 40 TS n = 40 p
Characteristics
Age (years) 65 ± 10 72 ± 8§ 69 ± 9 0.01 vs Ctrl
Height (cm) 158 ± 6 147 ± 7§ 159 ± 10 0.01 vs TS
0.02 vs TS
Weight (Kg) 65.9 ± 9 62 ± 11 69 ± 9§ 0.05 vs Ctrl
BMI (Kg/m2) 27 ± 8 29 ± 5 26 ± 3§ 0.01 vs BE
Exposure and physiological characteristics
Tobacco index (Pack/yr) - - 50 ± 30
Biomass index (Hrs/year of exposure) - 230 ± 132 -
FEV1 (% predicted) 107.8 ± 8.7 62.1 ± 25.6§ 49.5 ± 23.9§ 0.01 vs Ctrl
0.03 BE vs TS
FVC (% predicted) 109 ± 9 78 ± 19§ 82 ± 14§ 0.01 vs Ctrl
FEV1/FVC ratio 91 ± 9.5 53 ± 16§ 56 ± 15§ 0.01 vs Ctrl
Bronchodilator response (FEV1; %) - 9.54 ± 17 9.14 ± 8 0.883**
PaO2 (mmHg) - 53 ± 7 59 ± 10 0.056**
PaCO2 (mmHg) - 34 ± 4 32 ± 5 0.136**
6MWT (m) - 274 ± 155 327 ± 142 0.075**
SaO2 (%) - 88 ± 5 91 ± 5 0.039**
Chronic respiratory questionnaire
Dyspnea - 21 ± 10 17 ± 8 0.098**
Fatigue - 19 ± 5 20 ± 5 0.711**
Master - 37 ± 7 36 ± 9 0.570***
Control - 22 ± 4 22 ± 5 0.988**
Total score - 99 ± 15 95 ± 17 0.283**
GOLD stage
I - 8 (20) 8 (20)
0.075*
II - 25 (63) 15 (38)
III - 6 (15) 12 (30)
IV - 1 (2.) 5 (12)
Exacerbation rate/yr (min-max) - 1.27 (1-3) 1.38 (1-3) 0.495**
Data are presented as mean ± SD unless otherwise indicated. Ctrl = Control; BE = biomass exposure; TS: tobacco smoking; BMI: biomass mass index; FEV1: forced
expiratory volume in one second; FVC: forced vital capacity;% predicted: percentage of the predicted value. For GOLD stage figures are presented as number (%).
Statistical tests: §ANOVA-Tukey test; *X2 test; **Student-T test; ***Welch test. All comparisons with Ctrl and TS were against BE after Bonferroni adjustments.
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ratio were lower in TS and BE than in controls (Table 1).
Finally, it is important to note that in terms of the
GOLD classification, BE patients differ of TS patients
because the majority (83%) of them are included within
stages I and II, whereas TS patients are more homoge-
nously distributed, although this difference was not sta-
tistically significant (Table 1, p = 0.075). No differences
in the rate of exacerbations were found.
MMPs plasma concentrations
Plasma concentration of MMP-1, MMP-7 (Figure 1),
MMP-9 and the MMP-9/TIMP-1 complex (Figure 2)showed a significant increase both in tobacco smokers
and BE groups in comparison with the NS control
group; however, no significant differences were found
among the COPD groups (Table 2).CRP plasma levels in COPD patients
There was a significant increase in CRP plasma levels
both in tobacco smokers and BE COPD patients com-
pared with NS control subjects (Figure 3). Despite the
scattered picture that can be observed in the obtained
































































Figure 1 Plasma levels of MMP-1 and MMP-7 in COPD groups compared with NS healthy women (controls), and relationship between
plasma MMP-1 and MMP-7 and FEV1 (% predicted). There was a significant difference between BE and TS with NS healthy subjects. No
difference was found among COPD groups: (A) MMP-1. (B) MMP-1 between MMP-1 or MMP-7 and FEV1 (% predicted) in COPD and NS healthy
women performed with the Pearson correlation coefficient (r). (C) MMP-1; r = 0.4904 and p <0.0001. (D) MMP-7; r = 0.2902 and p <0.0013. Results













































































Figure 2 There were significant differences among BE and TS groups when compared with NS healthy women. COPD groups did not
show any difference: (A) MMP-9. (B) MM9-9/TIMP-1 complex. Relationship between MMP-9 and MM9-9/TIMP-1 complex with the FEV1 (% predicted) in
COPD and NS healthy women was performed with the Pearson correlation coefficient (r). (C) MMP-9; r = 0.8037 and p <0.0001; (D) MMP-9/TIMP-1
complex; r = 0.2150 and p <0.0163. Results are expressed as mean ± SD; p <0.01. NS (▪). TS (▲). BE (●).
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Table 2 Plasma concentration of MMPs, MMP-9/TIMP-1 complex and C-reactive protein
Control BE TS p
Molecule
MMP-1 (ng/mL) 1.62 ± 0.71 4.24 ± 2.17* 3.86 ± 2.71* 0.01
MMP-7 (ng/mL) 1.79 ± 0.26 2.63 ± 1.12* 2.87 ± 1.26* 0.01
MMP-9 (ng/mL) 4.46 ± 0.65 7.97 ± 3.53* 9.07 ± 2.84* 0.01
MMP-9/TIMP-1 (pg/mL) 0.18 ± 0.17 0.25 ± 0.18 0.32 ± 0.21* 0.05
C-reactive protein (ng/mL) 12.34 ± 6.04 32.89 ± 21.29* 35.49 ± 21.19* 0.05
BE: Biomass exposure; TS: Tobacco smoking.
Data are express as means ± SD. *ANOVA-Tukey test compared with Controls.
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An inverse correlation between MMP-1, MMP-7, MMP-
9, MMP-9/TIMP-1 and CRP plasma concentrations with















































Figure 3 Plasma levels of the C-reactive protein (CRP) in COPD
and NS healthy women, and relationship between CRP and
FEV1 (% predicted). There were significant differences among BE
and TS groups when compared with NS healthy women. COPD
groups did not show difference among them: (A) plasma levels of
CRP. (B) Relationship between plasma levels of CRP in COPD and NS
healthy women with the FEV1 (% predicted) performed with the
Pearson correlation coefficient (r). r = 0.4227 and p <0.0001. Results
are expressed as mean ± SD; p <0.01. NS (▪). TS (▲). BE (●).groups when compared to control group was observed
(Figures 1, 2 and 3).
Discussion
The main findings of this work are that: 1) metallopro-
teinases 1, 7, and 9, the MMP-9/TIPM-1 ratio and CRP
concentrations are increased in plasma of subjects with
COPD associated to BE, and: 2) an association among
these increases and FEV1 exists.
Several studies carried out in different populations
around the world have established that domestic expos-
ure to biomass solid fuels combustion products is now
considered an important risk factor for COPD, mainly in
developing countries [3,4,6,18]. A number of similarities
including mortality among COPD associated with TS
and BE have been observed [3,6]. However, information
on the possible role of candidate molecules already
involved in the pathogenesis of COPD associated with
tobacco exposure is scant in BE [6]. In the present
work, we studied the possible role of some of those
molecules. All study subjects selected were women be-
cause most patients with COPD secondary to domestic
BE reported in Mexico are females [4,5,12].
MMPs play an important role in the turnover of
almost all extracellular matrix molecules and are there-
fore probably involved in COPD pathogenesis [8,19].
An increase in serum or plasma MMP-1 and MMP-7
concentration in COPD associated to tobacco smoking
has already been demonstrated. Our current findings
in BE occur in a similar way, suggesting that these
enzymes could be involved in interstitial EM turnover
[20-22]. MMP-9 plasma levels and activity have been
extensively studied in patients with COPD secondary to
tobacco smoke, demonstrating an active role of these
enzymes during the inflammatory process that character-
izes COPD, especially in the degradation of interstitial and
basal membranes molecules of EM, such as types I and IV
collagen and elastic fibers [23-25]. Additionally, an
increase of MMP-9 has been reported in sputum, blood
and lung tissue from smokers with COPD [26-30]. On
the other hand, MMP-9 is inhibited by TIMP-1 and
an imbalance in the MMP-9/TIMP-1 ratio could be
Montaño et al. Respiratory Research 2014, 15:74 Page 6 of 7
http://respiratory-research.com/content/15/1/74involved in COPD pathogenesis. In this regard, Kang
et al demonstrated a correlation among the increase
in the MMP-9/TIMP-1 complex in lung tissue from
smokers and the airflow obstruction observed [31] and
Higashimoto et colleagues [20] found that circulating
TIMP-1 concentration was significantly higher in stable
COPD patients. This and our report suggest that excess
amounts of TIMP-1 compared with those of MMP-9
may be related to airway narrowing. Moreover, our
study showed an increase in the MMP-9/TIMP-1 com-
plex that inversely correlated with airflow obstruction
in both smokers and BE COPD patients, suggesting a
role in COPD associated to BE as it occurs in tobacco
smokers.
The increase of CRP plasma concentration has been
observed in patients with COPD associated with tobacco
exposure as well as in former smokers, suggesting that
the inflammatory process persists even when the exposure
to a risk factor has ceased [32]. Moreover, Higashimoto et
colleagues examined various inflammatory markers where
only serum CRP and MMP-9 levels were related to FEV1
decline [33]. CRP plasma concentration in biomass
smoke-exposed women was previously studied in a
group of subjects with COPD related to BE [34]. Although
the study sample was small (11 non-smoking subjects),
those data and ours suggest that these women develop
a systemic inflammation similar to that observed in
smokers. In this context, the association showing that
the lower the FEV1 the higher the CRP levels, supports
the possible role of CRP as a biomarker of systemic
inflammation in BE. Our results also show that the
history and annual rate of exacerbations did not affect
the levels of the studied molecules since the frequency
is similar in both groups of COPD.Conclusions
We report an increase of MMP-1, MMP-7, MMP-9,
MMP-9/TIMP-1 ratio and CRP plasma concentrations
and a correlation with FEV1 in women with COPD asso-
ciated to BE that is similar to that observed in smokers
with COPD. Further research is needed to clarify if these
MMPs and the CRP participate in the pathogenesis of
COPD in women exposed to BE.Abbreviations
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